Drug intelligence / Profile preview

heparin + prostacyclin

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of heparin and prostacyclin (epoprostenol) used as an anticoagulant therapy, particularly in continuous renal replacement therapy (CRRT) and other extracorporeal circuits. The combination leverages heparin's inhibition of coagulation factors and prostacyclin's inhibition of platelet aggregation to provide effective anticoagulation while potentially reducing side effects. Prostacyclin induces a "heparin-sparing effect," which can reduce the dosage and side effects of heparin while maintaining effective anticoagulation.

Targets

ATIII (Antithrombin III)PTGIR (Prostanoid IP Receptor)F2 (Thrombin)

Beyond the preview

Go deeper on heparin + prostacyclin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on heparin + prostacyclin.

Explore the full profile